Newly formed microRNA drug shop Mirrx Therapeutics has named its senior management and board of directors.
The company's CEO is Palle Schelde, who is currently investment director at Mirrx investor Inventure Capital. He previously served as research assistant at the National Cancer Society in Denmark, and held positions at Bayer and Akzo Nobel.
Mirrx's CSO is Thorlief Moller, who also founded the company. Moller previously served as an intellectual property consultant and had founded Stealth Biotech, out of which Mirrx was spun.
Sitting on Mirrx's board is John Riis Mortensen, investment director of Vecata, another group that has invested in Mirrx; Finn Cilius Nielsen, a professor of clinical molecular biology at the University of Copenhagen Rigshospitalet; and Ole Bitsch-Jensen, investment director at Seed Capital, which also invested in Mirrx.
Moller and Schelde are also company directors.
Tekmira Pharmaceuticals has appointed Daniel Kisner as its new chairman. He will replace Michael Forrest, who was appointed chairman in 1998 and has resigned from the company.
The company has also named Frank Karbe and Kenneth Galbraith as new independent directors.
Kisner is currently a venture partner at venture capital firm Abington Ventures. He previously served as CEO of Caliper Technologies and COO of antisense shop Isis Pharmaceuticals. He has also held positions with Abbott Laboratories and SmithKline Beckman Pharmaceuticals.
Karbe is currently executive vice president and CFO of Exelixis. Before this, he worked at Goldman Sachs, specializing in corporate finance and mergers and acquisitions.
Galbraith is currently a general partner at venture capital group Ventures West. He served as chairman and interim CEO of AnorMed prior to its sale to Genzyme. Before that, he was executive vice president and CFO of QLT.
Expressed RNAi shop Benitec has named John Chiplin as a director.
Previously, he was CEO and managing director of Arana Therapeutics, which was acquired by Cephalon. Before that, he was head of UK investment fund ITI Life Sciences.